This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LBPH Longboard Pharmaceuticals (LBPH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Longboard Pharmaceuticals Stock (NASDAQ:LBPH) 30 days 90 days 365 days Advanced Chart Get LBPH alerts:Sign Up Key Stats Today's Range$59.98▼$59.9850-Day Range$59.50▼$59.9852-Week Range$27.35▼$60.03VolumeN/AAverage Volume1.37 million shsMarket Capitalization$2.34 billionP/E RatioN/ADividend YieldN/APrice Target$65.67Consensus RatingHold Company Overview Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California. Read More Receive LBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Longboard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LBPH Stock News HeadlinesH Lundbeck A/S (HLUNAC.XD)February 9, 2025 | finance.yahoo.comH. Lundbeck A/S (HLUN-A.CO)December 18, 2024 | finance.yahoo.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 14 at 2:00 AM | The Oxford Club (Ad)Longboard Pharmaceuticals' SWOT analysis: bexicaserin potential drives stock outlookDecember 18, 2024 | investing.comLundbeck acquires all outstanding shares of Longboard PharmaDecember 5, 2024 | msn.comBright Minds initiated at outperform by Baird, Longboard takeover citedNovember 26, 2024 | msn.comHold Rating for Longboard Pharmaceuticals Amidst Acquisition Uncertainty and Speculative RisksNovember 13, 2024 | markets.businessinsider.comLongboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)November 12, 2024 | finance.yahoo.comSee More Headlines LBPH Stock Analysis - Frequently Asked Questions How were Longboard Pharmaceuticals' earnings last quarter? Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) released its quarterly earnings results on Thursday, August, 1st. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.10. Read the conference call transcript. When did Longboard Pharmaceuticals IPO? Longboard Pharmaceuticals (LBPH) raised $75 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor acted as the underwriters for the IPO. What other stocks do shareholders of Longboard Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Longboard Pharmaceuticals investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD). Company Calendar Last Earnings8/01/2024Today8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LBPH CIK1832168 Webwww.longboardpharma.com Phone619-592-9775FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Longboard Pharmaceuticals$65.67 High Price Target$90.00 Low Price Target$44.00 Potential Upside/Downside+9.5%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$54.42 million Net MarginsN/A Pretax MarginN/A Return on Equity-33.03% Return on Assets-30.90% Debt Debt-to-Equity RatioN/A Current Ratio15.97 Quick Ratio15.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book35.92Miscellaneous Outstanding Shares39,050,000Free Float37,234,000Market Cap$2.34 billion OptionableOptionable Beta1.00 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:LBPH) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longboard Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longboard Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.